앰겔러티는 삽화편두통환자 1773명과 만성편두통환자 1113명을 대상으로 진행한 임상시험을 근거로 허가됐다.
Emgality was approved based on a clinical trial conducted in 1,773 patients with episodic migraine and 1,113 patients with chronic migraine.